# Patrick M. Forde

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/patrick-m-forde/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,114 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 66 |
| i10-index | 163 |
| Last Known Institution | Bloomberg (United States) |
| OpenAlex ID | https://openalex.org/A5059543131 |
| ORCID iD | 0000-0001-6925-6344 |
| Works | 546 |

## Researcher papers

Showing 12 of 14.

- [Neoadjuvant PD-1 Blockade in Resectable Lung Cancer](https://scholariq.org/papers/neoadjuvant-pd-1-blockade-in-resectable-lung-cancer/)
- [Genome-wide cell-free DNA fragmentation in patients with cancer](https://scholariq.org/papers/genome-wide-cell-free-dna-fragmentation-in-patients-with-cancer/)
- [Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer](https://scholariq.org/papers/evolution-of-neoantigen-landscape-during-immune-checkpoint-blockade-in-non-small/)
- [Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)](https://scholariq.org/papers/pathologic-features-of-response-to-neoadjuvant-anti-pd-1-in-resected-non-small/)
- [Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers](https://scholariq.org/papers/transcriptional-programs-of-neoantigen-specific-til-in-anti-pd-1-treated-lung/)
- [Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer](https://scholariq.org/papers/multisystem-immune-related-adverse-events-associated-with-immune-checkpoint/)
- [Detection and characterization of lung cancer using cell-free DNA fragmentomes](https://scholariq.org/papers/detection-and-characterization-of-lung-cancer-using-cell-free-dna-fragmentomes/)
- [Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors](https://scholariq.org/papers/pneumonitis-in-non-small-cell-lung-cancer-patients-receiving-immune-checkpoint/)
- [Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels](https://scholariq.org/papers/association-of-high-tumor-mutation-burden-in-non-small-cell-lung-cancers-with/)
- [Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations](https://scholariq.org/papers/characterization-of-298-patients-with-lung-cancer-harboring-met-exon-14-skipping/)
- [Epigenetic therapy inhibits metastases by disrupting premetastatic niches](https://scholariq.org/papers/epigenetic-therapy-inhibits-metastases-by-disrupting-premetastatic-niches/)
- [Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non–small cell lung cancer](https://scholariq.org/papers/initial-results-of-pulmonary-resection-after-neoadjuvant-nivolumab-in-patients/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [Bloomberg (United States)](https://scholariq.org/institutions/bloomberg-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.